Many patients with overweight or obesity discontinue glucagon-like peptide-1 (GLP-1) receptor agonist therapy within o ...

GLP-1) receptor agonists, which are used to treat type 2 diabetes and/or obesity, were linked to vision problems in a small ...

A network meta-analysis reveals age-dependent variations in efficacy of popular diabetes drugs, with SGLT2 inhibitors showing ...

Ozempic and Wegovy are a set of drugs that cause weight loss by mimicking a natural hormone called glucagon-like peptide-1 ...

As drugs like Ozempic and Mounjaro continue to skyrocket in usage, doctors are encountering more cases linking them to ...

The use of glucagon-like peptide-1 receptor agonists is likely to increase the risks of inadequate bowel preparation for colonoscopy, according to a study published Feb. 12 in The American Journal of ...

Over 40% of U.S. adults meet the medical classification for obesity, according to the Centers for Disease Control and ...

Allurion’s CEO confirmed to Medical Device Network that the company has changed advertising, patient follow-up, and physician ...

The Janus Henderson Global Sustainable Equity Fund returned -5.88% for Q4 2024. Click here to read the full commentary.

The glucagon-like peptide-1 receptor agonist exenatide does not yield improvement in measures of Parkinson disease severity.

Weight-inclusive health care is the provision of equitable care without perpetuating weight stigma among patients of all body shapes and sizes.

The Janus Henderson Global Sustainable Equity Managed Account Portfolio returned -5.71% (gross) for Q4 2024. Click here to ...